Youssef Mina M G, Namour Alfred, Youssef Omar Z, Morsi Ahmed
1Department of Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
2Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Indian J Surg Oncol. 2018 Sep;9(3):300-306. doi: 10.1007/s13193-017-0689-3. Epub 2017 Aug 15.
Oncoplastic surgery (OPS) has emerged as a new approach for extending breast conserving surgery (BCS) possibilities, reducing both mastectomy and re-excision rates, while avoiding breast deformities. OPS is based upon the integration of plastic surgery techniques for immediate reshaping after wide excision for breast cancer. This is a prospective feasibility cohort study of oncoplastic breast surgery after neoadjuvant chemotherapy that was carried at the National Cancer Institute, Cairo University and included 70 patients. The primary outcome was the local recurrence rate. Secondary outcomes included survival and margins obtained as well as cosmetic outcomes. Survival analysis was performed. Oncoplastic breast surgery did not compromise oncologic safety in the patients included in the study. It even allowed wider margins of resection which could be associated with better oncologic outcomes. At the same time, it gave a better cosmetic outcome and therefore higher patient satisfaction. Oncoplastic breast surgery includes a wide spectrum of surgical techniques, ranging from the basic level I techniques in breast conserving surgery to the more complex procedures of level II which are broadly classified into volume replacement (therapeutic mammoplasty) and volume displacement procedures. We suggest that oncoplastic breast surgery techniques should be the standard of care in breast surgery. They are the basis for breast conserving surgery techniques in early breast cancer. In our experience, oncoplastic surgery is feasible in locally advanced tumours after downstaging with neoadjuvant chemotherapy without compromising the oncologic safety.
肿瘤整形手术(OPS)已成为一种新方法,可扩大保乳手术(BCS)的可能性,降低乳房切除术和再次切除率,同时避免乳房畸形。OPS基于将整形手术技术整合用于乳腺癌广泛切除术后的即刻重塑。这是一项在开罗大学国家癌症研究所进行的新辅助化疗后肿瘤整形乳房手术的前瞻性可行性队列研究,纳入了70例患者。主要结局是局部复发率。次要结局包括生存率、切缘情况以及美容效果。进行了生存分析。肿瘤整形乳房手术并未损害研究中纳入患者的肿瘤学安全性。它甚至允许更宽的切除切缘,这可能与更好的肿瘤学结局相关。同时,它提供了更好的美容效果,因此患者满意度更高。肿瘤整形乳房手术包括广泛的手术技术,从保乳手术的基本I级技术到更复杂的II级手术,大致分为容积置换(治疗性乳房成形术)和容积移位手术。我们建议肿瘤整形乳房手术技术应成为乳房手术的标准治疗方法。它们是早期乳腺癌保乳手术技术的基础。根据我们的经验,在新辅助化疗降期后,肿瘤整形手术在局部晚期肿瘤中是可行的,且不影响肿瘤学安全性。